Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.

ABSTRACT: Immune checkpoint blockers (ICB) have emerged as a promising new class of antitumor agents which significantly change the treatment landscape in a range of tumors; however, cancer patients benefited from ICB-based immunotherapy remains limited, scoring the need to explore the combination treatments with synergistic mechanisms of action. Axl receptor tyrosine kinase critically involves in the carcinogenesis of multiple cancers due to its dual roles in both promoting cancer invasion and metastasis and suppressing myeloid cell activation and function. Here, we found that Axl inhibition by tyrosine kinase inhibitors induces antitumor efficacy critically depending on immune effector mechanisms in two highly clinical relevant murine tumor models. Mechanistic investigation defined that Axl inhibi

SUBMITTER: Guo Z 

PROVIDER: S-EPMC5685707 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature